Ionis Pharmaceuticals Inc  

(Public, NASDAQ:IONS)   Watch this stock  
Find more results for NASDAQ:ISIS
40.40
-0.57 (-1.39%)
After Hours: 40.48 +0.08 (0.20%)
May 2, 5:46PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 38.73 - 41.17
52 week 30.93 - 71.50
Open 40.86
Vol / Avg. 1.34M/1.82M
Mkt cap 4.88B
P/E     -
Div/yield     -
EPS -0.75
Shares 120.73M
Beta 2.13
Inst. own 87%
Jul 13, 2016
Ionis Pharmaceuticals Inc R&D Day - 8:00AM EDT - Add to calendar
Jun 7, 2016
Ionis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference - 8:00PM EDT - Add to calendar
Jun 3, 2016
Ionis Pharmaceuticals Inc Annual Shareholders Meeting - 5:00PM EDT - Add to calendar
May 4, 2016
Ionis Pharmaceuticals Inc at Deutsche Bank Health Care Conference - 8:00PM EDT - Add to calendar
May 4, 2016
Q1 2016 Ionis Pharmaceuticals Inc Earnings Call - 10:30AM EDT - Add to calendar
May 4, 2016
Q1 2016 Ionis Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
Apr 21, 2016
Ionis Pharmaceuticals to Discuss Neurological Disease Programs Highlighted at the AAN Conference Call - Webcast
Apr 13, 2016
Ionis Pharmaceuticals Inc at Needham Healthcare Conference
Mar 15, 2016
Ionis Pharmaceuticals Inc at Barclays Global Healthcare Conference
Mar 14, 2016
Ionis Pharmaceuticals Inc at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -138.52% -31.12%
Operating margin -122.05% -26.70%
EBITD margin - -23.10%
Return on average assets -29.48% -9.23%
Return on average equity -128.42% -38.50%
Employees 428 -
CDP Score - -

Address

2855 Gazelle Ct
CARLSBAD, CA 92010-6670
United States - Map
+1-760-9319200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is a ribonucleic acid-targeted (RNA-targeted) drug discovery and development company. The Company is focused on discovering and developing antisense drugs. Its antisense drugs are used to treat a range of diseases, including cardiovascular; metabolic; severe and rare diseases, including neurological disorders, and cancer. Volanesorsen is a drug indicated to treat patients with high triglyceride levels, including patients with a genetic condition called familial chylomicronemia syndrome (FCS) and patients with partial lipodystrophy. It is focused on bringing its late-stage Phase III drugs, nusinersen, volanesorsen and IONIS-TTR to the market. Its lipid-lowering product, KYNAMRO (mipomersen sodium) injection, is on the market in the United States for patients with homozygous familial hypercholesterolemia (HoFH). Its products also include Alicaforsen, IONIS-DMPK-2.5, Plazomicin and IONIS-GCGR.

Officers and directors

Stanley T. Crooke M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 70
Bio & Compensation  - Reuters
Elizabeth L. Hougen Chief Financial Officer, Senior Vice President - Finance
Age: 54
Bio & Compensation  - Reuters
B. Lynne Parshall J.D. Chief Operating Officer, Corporate Secretary, Director
Age: 61
Bio & Compensation  - Reuters
Patrick R. O'Neil Esq. Senior Vice President, Legal, General Counsel and Corporate Secretary
Age: 42
Bio & Compensation  - Reuters
C. Frank Frank Bennett Ph.D. Senior Vice President - Antisense Research
Age: 59
Bio & Compensation  - Reuters
Richard S. Geary Ph.D. Senior Vice President - Development
Age: 58
Bio & Compensation  - Reuters
Brett P. Monia Ph.D. Senior Vice President - Drug Discovery and Corporate Development
Age: 54
Bio & Compensation  - Reuters
Sarah Boyce Chief Business Officer
Age: 44
Bio & Compensation  - Reuters
Joseph Loscalzo M.D., Ph.D. Director
Age: 63
Bio & Compensation  - Reuters
Spencer R. Berthelsen M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters